贝伐珠单抗联合顺铂腹腔给药治疗胃癌腹水的效果

Abstract
Figure/Table
References (27)
Related Citation (15)

Download: PDF (590 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To observe the efficacy of Bevacizumab combined with Cisplatin in the treatment of gastric cancer with ascites. Methods A total of 102 patients with gastric cancer and ascites admitted to the No.904 Hospital of PLA Joint Service Support Force from June 2017 to June 2020 were selected. The patients were divided into control group and study group by random number method, with 51 cases in each group. The control group was given Cisplatin intraperitoneal administration, and the research group was combined with Bevacizumab on the basis of the control group, with 21 days as a treatment cycle, a total of two cycles of treatment. The efficacy of the two groups was compared. The levels of tumor markers (carbohydrate antigen [CA] 125, carcinoembryonic antigen [CEA], CA199), and mRNA expression of matrix metalloproteinase (MMP)-2, Gil1, and MMP-9 in ascites were compared between the two groups. The incidence of adverse reactions in the two groups was recorded. Results The objective remission rate and disease control rate in the study group were higher than those in the control group, and the differences were statistically significant (P ＜ 0.05). After two cycles of treatment, the levels of CEA, CA125, and CA199 in ascites in both groups were lower than before treatment, and those in the study group were lower than those in the control group, with statistical significance (P ＜ 0.05). After two cycles of treatment, the mRNA expressions of MMP-2, Gil1, and MMP-9 in ascites in both groups were lower than before treatment, and those in the study group were lower than those in the control group, with statistical significance (P ＜ 0.05). There was no significant difference in the total incidence of adverse reaction between the two groups (P ＞ 0.05). Conclusion Intraperitoneal administration of Bevacizumab combined with Cisplatin in the treatment of ascites in gastric cancer can effectively alleviate the progression of ascites with reliable efficacy.

Key words： Bevacizumab Cisplatin Intraperitoneal administration Gastric cancer Ascites Curative effect

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	TANG Xiaolong1 CHEN Xufeng1 ZHENG Yang1 YANG Shenglan1 CHEN Liang2

Cite this article:

TANG Xiaolong1 CHEN Xufeng1 ZHENG Yang1 YANG Shenglan1 CHEN Liang2. Effect of Bevacizumab combined with Cisplatin in the treatment of gastric cancer with ascites[J]. 中国医药导报, 2021, 18(23): 88-91,107.

URL:

https://www.yiyaodaobao.com.cn/EN/ OR https://www.yiyaodaobao.com.cn/EN/Y2021/V18/I23/88

[1] 郭嘉欣，徐远义.胃癌癌相关成纤维细胞研究进展[J].解放军医学杂志，2021，46（3）：306-310.
[2] 丁以绚，赵桂梅，李丽华，等.基于网络药理学分析附子理中汤治疗晚期胃癌的作用机制[J].浙江中医药大学学报，2021，45（4）：398-405.
[3] 沈李婷，李金洋，李先峰，等.m6A去甲基化酶ALKBH5抑制胃癌细胞运动侵袭和Wnt信号通路活性的机制[J].第三军医大学学报，2021，43（6）：459-466.
[4] 谢晓东，强永虎，刘沈林，等.健脾养胃方联合新辅助化疗对胃癌患者临床疗效的影响及机制研究[J].南京中医药大学学报，2021，37（2）：198-204.
[5] 邱亚展，吴进兵，胡波，等.贝伐珠单抗联合顺铂腹腔灌注治疗胃癌恶性腹腔积液[J].肿瘤基础与临床，2019，32（3）：201-204.
[6] 中华人民共和国卫生部.中国常见恶性肿瘤诊治规范[M].北京：北京医科大学、中国协和医科大学联合出版社，1991.
[7] 杨学宁，吴一龙.实体瘤治疗疗效评价标准-RECIST[J].循证医学，2004，4（2）：85-90，111.
[8] 檀碧波，狄岩，李勇，等.铜绿假单胞菌注射液联合洛铂腹腔注射治疗胃癌恶性腹腔积液的效果[J].河北医药，2021，43（3）：434-436，442.
[9] Zheng LN，Wen F，Xu P，et al. Prognostic significance of malignant ascites in gastric cancer patients with peritoneal metastasis：A systemic review and meta-analysis [J]. World J Clin Cases，2019，7（20）：3247-3258.
[10] Honda M，Kawamura H，Kobayashi H，et al. An ascites grading system for predicting the prognosis of gastric cancer with peritoneum dissemination [J]. Ann Gastroenterol Surg，2020，4（6）：660-666.
[11] 董媛，师贞宗.早期循环式腹腔热灌注化疗对胃癌合并腹腔积液患者血清MMPs与CEA的影响[J].兰州大学学报：医学版，2019，45（3）：49-53.
[12] 刘涛，杨燕，刘博，等.联合检测胸腹腔积液sCD44V6，CEA，CYFRA21-1，CA199，NSE，CA125对良恶性疾病鉴别诊断价值研究[J].现代检验医学杂志，2020，35（2）：53-55，64.
[13] 郭建峰.早期循环式腹腔热灌注化疗对胃癌合并腹腔积液的效果及对患者血清MMPs与CEA的影响[J].实用癌症杂志，2016，31（9）：1414-1416.
[14] 王娴，熊盾，何兴瑞.重组人血管内皮抑制素联合顺铂治疗晚期胃癌合并恶性腹腔积液的疗效及安全性分析[J].临床和实验医学杂志，2018，17（6）：605-607.
[15] 吕行，张进儒，宁鹏，等.紫杉醇联合顺铂腹腔热灌注化疗对胃癌恶性腹腔积液疗效的临床研究[J].中国医学前沿杂志：电子版，2014，6（10）：126-128.
[16] 阎雷.顺铂腹腔灌注联合黄芪多糖治疗胃癌合并恶性腹腔积液的临床疗效[J].实用心脑肺血管病杂志，2018， 26（z1）：242-244.
[17] 李阳，周欣亮，王玉栋，等.分子靶向药物治疗恶性腹腔积液的研究进展[J].肿瘤防治研究，2013，40（10）：1007-1010.
[18] 王霞，姜润学.贝伐珠单抗联合腹腔热灌注化疗治疗胃癌伴恶性腹腔积液效果观察[J].肿瘤研究与临床，2020，32（10）：701-704.
[19] 陆媛，蔡永广.贝伐珠单抗应用于非小细胞肺癌中的研究进展[J].中国现代医生，2020，58（8）：187-192.
[20] 王巧，姜向阳.卵巢甲状腺肿并假Meigs综合征与血清CA125升高1例并文献复习[J].中国计划生育学杂志，2020，28（2）：300-302.
[21] 邱双成，曾耀，李伟翔.CEA、CA153、CA125、CA199联合检测在肺癌诊断中的价值[J].中国医药科学，2019，9（17）：129-131.
[22] 王慧鸽，程玲，赖娟，等.血清AFP、CEA、CA199和CA125联合检测在宫颈癌诊断中的价值[J].医学综述，2020， 26（1）：169-173.
[23] 沈萍萍，蒋素敏，吴益群，等.血清CEA、CA199及SLPI联合检测在胃癌诊断中的价值[J].中国现代医生，2019， 57（22）：13-16.
[24] 王宁，付立业，隋承光，等.胃癌患者血清中IGF-1与CEA、CA125、CA199、CA724水平的相关性分析及在胃癌诊断中的意义[J].中国实验诊断学，2021，25（2）：194-197.
[25] 苏红领，杨湘敏，高正军.血清CEA、TK1、CA199、CA125联合检测对胃癌的诊断效果研究[J].实用癌症杂志，2019，34（8）：1301-1303.
[26] 杨冬野，焦洋，杜志坚，等.猪苓多糖注射液联合顺铂腹腔给药治疗胃癌腹腔积液患者的疗效观察[J].河北医药，2018，40（5）：725-727，731.
[27] 周军，米登海，沈少艳，等.贝伐珠单抗联合化疗治疗卵巢癌腹腔积液的Meta分析[J].医学研究杂志，2020，49（1）：153-157，162.